Silvercrest Asset Management’s Chembio diagnostics, Inc. CEMI Stock Holding History

Silvercrest Asset Management’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-681,189	Closed	-$3.11M	–	814
2019 Q4	$3.11M	Sell	681,189 -29,067	-4%	-$142K	0.02%	423
2019 Q3	$4.35M	Buy	+710,256	New	+$4.23M	0.04%	363

Other funds holding CEMI

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Friess Associates Greenville, Delaware $59.9M AUM 3.42% 1-Year Est. Return

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Silvercrest Asset Management's CEMI Position: Q1 2020 in Review

Silvercrest Asset Management sold out of Chembio diagnostics, Inc. (CEMI) in Q1 2020, closing a stake of 681,189 shares — an estimated $3.11M sold.

Silvercrest Asset Management first reported a position in CEMI in Q3 2019 and held it in 2 quarters. The position peaked at $4.35M in Q3 2019. 42 funds tracked by Wall St. Rank hold CEMI as of Q1 2020.

Silvercrest Asset Management reported no remaining Chembio diagnostics, Inc. position as of Q1 2020 after selling out during the quarter.
Silvercrest Asset Management sold 681,189 Chembio diagnostics, Inc. shares in Q1 2020, an estimated $3.11M.
Silvercrest Asset Management first reported a position in Chembio diagnostics, Inc. in Q3 2019 and held it in 2 quarters.
Silvercrest Asset Management's Chembio diagnostics, Inc. position peaked at $4.35M in Q3 2019.
42 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q1 2020.

Based on Silvercrest Asset Management's 13F filing for Q1 2020, filed 15 May 2020.